RxDoctor Payments Data

Heather Parnell

Women's Health · Bowling Green, KYNPI 1063684819

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,694 of the $5,225 with a category attached, or 89.8%. It is spread thinly across 33 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,576 and has fallen 60.4% since, to $625 in 2025. Among women's health clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,225in general payments, 2019–2025

Across 239 payments — averaging $21.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aspira Women's Health Inc$896
  • AbbVie$730
  • Astellas Pharma US Inc$714
  • Biogen$368
  • Mayne Pharma Commercial LLC$346
  • Exeltis, USA Inc.$301
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$4,69490%
  • Education$53110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,225 in reported general payments places this provider in the 95th percentile of 96 women's health providers in Kentucky.

See all women's health providers in Kentucky

Medicare billing

Part B allowed, 2024
$21,961
Medicare patients
82
Services billed
1,196

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron24$14,786
PremarinEstrogens, Conjugated26$8,037
Estradiol111$7,582
Estradiol (Twice Weekly)Estradiol14$1,829
ProgesteroneProgesterone, Micronized48$1,514
Clobetasol Propionate15$686
ValacyclovirValacyclovir Hcl15$622
Fluconazole21$213
Norethindrone18$139

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$714$14,78624 claims
PfizerPremarin$144$8,03726 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 96 women's health providers in Kentucky.

Other women's health in Bowling Green

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →